Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1450-1456

  Choi, Woonyoung ^a   Cogdell, David ^a   Feng, Yumei ^a,b   Hamilton, Stanley R ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

CES 2; Chemotherapy; p53; Phosphorylation; Transcription

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 2; FLUOROURACIL; IRINOTECAN; LUCIFERASE; MUTANT PROTEIN; NUCLEOTIDE; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; BINDING SITE; CARCINOMA CELL; CHROMATIN IMMUNOPRECIPITATION; COLON CARCINOMA; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG ACTIVITY; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRON; KNOCKOUT GENE; PROTEIN BINDING; PROTEIN EXPRESSION; REPORTER GENE; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION; WILD TYPE;

EID: 33846944684     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3271     Document Type: Article

References (58)

1. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998; 12:2973-83.
2. Prives C. Signaling to p53: breaking the MDM-2-p53 circuit. Cell 1998; 95:5-8.
3. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.
4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304-11.
5. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14:1815-23.
6. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11:3471-81.
7. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281:1677-9.
8. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Randisky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15:3032-40.
9. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJ Jr, Harris CC. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 1999; 96:3706-11.
10. Xiao G, Chicas A, Olivier M, Taya Y, Tyagi S, Kramer FR, Bargonetti J. A DNA damage signal is required for p53 to activate gadd45. Cancer Res 2000; 60:1711-9.
11. Bean LJ, Stark GR. Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm-2. J Biol Chem 2002; 277:1864-71.
12. Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, Owen-Schaub LB, Andreeff M, Reed JC, Zhang W.Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ 1998; 5:584-91.
13. Wu X, Bayle JH, Olson D, Levine AJ. The p53/Mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7:1126-32.
14. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B.WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
15. Harper JW, Adami GR, Wei N, Keuomarsi K, Elledge SJ. The p21 Cdk-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75:805-16.
16. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9.
17. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm-2. EMBO J 1999; 18:1805-14.
18. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, Fornace AJ Jr. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18:6845-54.
19. Sherley JL. Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration. J Biol Chem 1991; 266:24815-28.
20. Rivera A, Maxwell SA. The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J Biol Chem 2005; 280:29346-54.
21. Bean LJ, Stark GR. Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV. Oncogene 2001; 20:1076-84.
22. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999; 96:13777-82.
23. Latonen L, Taya Y, Laiho M. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts. Oncogene 2001; 20:6784-93.
24. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325-34.
25. Jabbur JR, Tabor AD, Cheng X, Wang H, Uesugi M, Lozano G, Zhang W. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene 2002; 21:7100-13.
26. Jabbur JR, Huang P, Zhang W. DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo. Oncogene 2000; 19:6203-8.
27. Shieh SY, Taya Y, Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, ser20, requires tetramerization. EMBO J 1999; 18:1815-23.
28. Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M, Haupt Y. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 1999; 18:3205-12.
29. Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H Jr, Cornell G. A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report. Cancer 1977; 39:34-40.
30. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 1972; 12:2717-9.
31. Fine S, Erlichman C, Kaizer L, Warr D, Gadalla T. Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. Breast Cancer Res Treat 1994; 30:205-9.
32. Zhang W, Ramdas L, Shen W, Song SW, Hu L, Hamilton SR. Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2. Cancer Biol Ther 2003; 2:572-8.
33. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996; 52:1103-11.
34. Pindel EV, Kedishvili NY, Abraham TL, Brzezinski MR, Zhang J, Dean RA, Bosron WF. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem 1997; 272:14769-75.
35. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002; 8:2605-11.
36. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988; 48:6863-71.
37. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 1999; 59:4228-32.
38. Jabbur JR, Zhang W. p53 antiproliferative function is enhanced by aspartate substitution at threonine 18 and serine 20. Cancer Biol Ther 2002; 1:277-83.
39. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001; 8:57-69.
40. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12:2831-41.
41. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, Berger SL. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999; 19:1202-9.
42. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002; 62:7316-27.
43. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001; 20:4601-12.
44. Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, Nieruchalski M, May E. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000; 19:649-60.
45. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004; 64:5078-83.
46. Liu X, Yue P, Khuri FR, Sun SY. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 2005; 65:9169-75.
47. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19:1735-43.
48. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188:2033-45.
49. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ Jr. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266:1376-80.
50. White KN, ¬Vale VL, ¬Hope DB. Identification of common form salicylates esterases in guinea-pig tissues similar to the microsomal aspirinase of liver. Biochem Soc Trans 1994; 22:220S.
51. Park YH, ¬Lee SS. Identification and characterization of capsaicin-hydrolyzing enzymes purified from rat liver microsomes. Biochem Mol Biol Int 1994; 34:351-60.
52. Mentlein R, ¬Schumann M, ¬Heymann E. Comparative chemical and immunological characterization of five lipolytic enzymes (carboxylesterases) from rat liver microsomes. Arch Biochem Biophys 1984; 234:612-21.
53. Nambu K, Miyazaki H, Nakanishi Y, Oh-e Y, Matsunaga Y, Hashimoto M. Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins. Biochem Pharmacol 1987; 36:1715-22.
54. Kojima A, Hackett NR, Crystal RG. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res 1998; 58:4368-74.
55. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10:2158-67.
56. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, Boland CR, Zeitz M, Hanski C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 2002; 101:23-31.
57. Bhonde MR, Hanski ML, Notter M, Gillissen BF, Daniel PT, Zeitz M, Hanski C. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 2006; 25:165-75.
58. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343:905-14.